mTOR (mechanistic/mammalian target of rapamycin) plays an important role in the development and proliferation of the body cells and acts on protein kinase complexes, such as mTOR complex 1 and 2 (mTORC1/2). Rapamycin, the first inhibitor of mTOR, has been approved as an immunosuppressant, that blocks T-cell activation and has been in use since 2000 for the prevention of kidney graft rejection. Temsirolimus, a drug manufactured by Pfizer Inc., used for the treatment of advanced renal cell carcinoma has been approved by the USFDA in 2007.
mTOR INHIBITORS THERAPEUTICS UNDER DEVELOPMENT (2017)
Further Pfizer Inc. is in the process of developing gedatolisib (PF-05212384) that deregulates the phosphoinositide 3-kinase (PI3K) and mTOR signaling pathways, for the treatment of acute myeloid leukemia, colorectal cancer, non-small cell lung cancer and breast cancer. Most of the drug candidates in the pipeline are being developed to be administered by the oral route of administration.
As of December 2017, the mTOR inhibitors therapeutics pipeline comprises of 30 drug candidates in different stages of development.
Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.